ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
Go back to ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027| (NASDAQ: IBRX) | Delayed: 7.22 -0.14 (1.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.36 | 52 Week High | $ | |||
| Open | $7.49 | 52 Week Low | $ | |||
| Day High | $7.55 | P/E | N/A | |||
| Day Low | $7.17 | EPS | $ | |||
| Volume | 9,870,259 | |||||
